The Motley Fool

Why I’d sell this FTSE 100 growth stock for its rival’s big dividend

The share price of private hospital group Mediclinic International (LSE: MDC) is down around 5% today as the market digests yet another mixed financial update from the firm. On the positive side, the company’s Southern African assets continue to perform well with local currency revenue up 4.1% and margins creeping upward. However, this performance was cancelled out by a decrease in revenue and margins in both its Swiss and UAE hospitals.

Overall, in constant currency terms, group revenue was flat and underlying EBITDA was down 5% year-on-year (y/y). While both revenue and profits were up in real terms due to the weak pound, investors should mainly concern themselves with how the business is actually performing since management can’t control currency movements.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Aside from South Africa, there was some good news on this front in the six months to September as management disclosed it was confident that struggling Middle Eastern operations would post positive sales and profit growth in H2. This is good to hear as some of the group’s hospitals in the Emirates have struggled with high staff turnover and weak demand following their acquisition. The company says doctor vacancies have now stabilised, but unfortunately the local market remains highly competitive, which is likely to keep margins well below group average for some time.

Overall, the company is not one I’d like to invest in today. Net debt following the reverse takeover of Al Noor Hospitals in 2015 is still relatively high at £1.6bn or 3.3 times full-year EBITDA, and problems in the UAE business have proven stubbornly difficult to put right. Add in a lofty valuation of 21 times trailing earnings and I see better places to invest my cash.

Utilising all the tools it has 

One company that’s caught my eye is water utility Severn Trent (LSE: SVT). It offers a solid 3.9% dividend yield and trades at 14 times earnings, despite its share price rising a respectable 27% over the past five years.

While regulated utilities are far from growth stars, Severn Trent’s management team has proven very capable of squeezing extra profits out of the business by cutting costs and exceeding regulatory efficiency targets that come with multi-million pound incentives.

For the year to March 2018, it is targeting outperforming outcome delivery incentives to the tune of £23m. On top of these bonus payments, management has found some £770m in cost efficiencies over the five-year review period from 2015-20. Together these have supported steady dividend increases while keeping customers’ average water bills the lowest in the UK.

Looking forward, the firm is prepared to see its regulated rates fall for the 2020-25 review period as regulators want to lower utility bills for consumers. This will, of course, be bad news for Severn Trent, which is why its share price has dropped 16% since May. But unlike competitors, it has proven very capable of cutting fat and hitting targets to maintain and grow profits.

With a bumper dividend, great recent operational history and increasingly attractive valuation, Severn Trent is one stock well worth a closer look.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Ian Pierce has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.